OnkoSight advanced NGS testing provides targeted gene content that is aligned with the latest guidelines from the National Comprehensive Cancer Network and the World Health Organization and provides insight into the most common types of cancer.

The assay panel also includes information on key biomarkers like tumor mutation burden and tumor-only microsatellite, which are necessary when profiling advanced-stage tumor malignancies.

New small-molecule drug targets hard-to-reach cancer-linked enzyme
Researchers have developed a new class of small-molecule drugs that show promise against a subset of pediatric leukemia with the NUP98-NSD1 chromosomal...

Gilead licenses immunotherapy from Jounce
Gilead Sciences has exclusively licensed the JTX-1811 novel cancer immunotherapy program from Jounce Therapeutics.

NCI, Cancer Research U.K. fund project to spur cancer research
The U.S. National Cancer Institute (NCI) has partnered with Cancer Research U.K. to fund Cancer Grand Challenges, an international initiative to support...

ESMO recommends use of NGS for advanced cancers
The European Society for Medical Oncology (ESMO) released its first recommendations for the use of next-generation sequencing (NGS) for patients with...